Victory Capital Management Inc. decreased its holdings in Audentes Therapeutics, Inc. (NASDAQ:BOLD) by 1.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 73,024 shares of the biotechnology company’s stock after selling 890 shares during the quarter. Victory Capital Management Inc. owned about 0.26% of Audentes Therapeutics worth $1,397,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in BOLD. Wells Fargo & Company MN raised its position in Audentes Therapeutics by 278.5% in the 1st quarter. Wells Fargo & Company MN now owns 7,747 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 5,700 shares during the last quarter. Citadel Advisors LLC purchased a new stake in Audentes Therapeutics in the 1st quarter valued at $184,000. State of Wisconsin Investment Board purchased a new stake in Audentes Therapeutics in the 2nd quarter valued at $210,000. Rhumbline Advisers purchased a new stake in Audentes Therapeutics in the 2nd quarter valued at $252,000. Finally, Bank of New York Mellon Corp raised its position in Audentes Therapeutics by 36.2% in the 1st quarter. Bank of New York Mellon Corp now owns 18,843 shares of the biotechnology company’s stock valued at $321,000 after purchasing an additional 5,009 shares during the last quarter. Hedge funds and other institutional investors own 77.01% of the company’s stock.
In other Audentes Therapeutics news, VP Suyash Prasad sold 8,000 shares of the firm’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $21.44, for a total value of $171,520.00. Following the sale, the vice president now directly owns 8,000 shares in the company, valued at $171,520. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Orbimed Advisors Llc sold 5,000 shares of the firm’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $22.35, for a total value of $111,750.00. The disclosure for this sale can be found here. Insiders sold 55,850 shares of company stock worth $1,136,970 over the last quarter. 47.30% of the stock is currently owned by company insiders.
WARNING: “Victory Capital Management Inc. Trims Position in Audentes Therapeutics, Inc. (BOLD)” was published by Markets Daily and is the sole property of of Markets Daily. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.themarketsdaily.com/2017/09/13/victory-capital-management-inc-trims-position-in-audentes-therapeutics-inc-bold.html.
Several analysts recently commented on BOLD shares. Zacks Investment Research upgraded shares of Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 price target for the company in a research report on Monday, July 17th. ValuEngine upgraded shares of Audentes Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, July 20th. Finally, Evercore ISI started coverage on shares of Audentes Therapeutics in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $23.00 price target for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. Audentes Therapeutics presently has an average rating of “Hold” and a consensus price target of $22.40.
Audentes Therapeutics, Inc. (NASDAQ:BOLD) opened at 24.28 on Wednesday. Audentes Therapeutics, Inc. has a 12 month low of $13.13 and a 12 month high of $24.50. The stock’s market cap is $674.60 million. The firm’s 50-day moving average is $24.35 and its 200-day moving average is $16.88.
Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.10). On average, equities analysts forecast that Audentes Therapeutics, Inc. will post ($3.53) earnings per share for the current fiscal year.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.